Predicting oliguria following indomethacin for treatment of patent ductus arteriosus

Am J Perinatol. 1994 May;11(3):220-2. doi: 10.1055/s-2008-1040750.

Abstract

Fifty-two consecutive infants who received intravenous indomethacin, 0.2 mg/kg, were reviewed to determine factors associated with the occurrence of oliguria. Serum creatinine and concentration prior to indomethacin did not predict the occurrence of oliguria. A mean urine output of less than 4.5 mL/kg/hr prior to the administration of indomethacin was the only factor that we determined to be associated with a significant risk of oliguria. Two infants developed symptomatic oliguria and both had a pre-indomethacin urine output less than 1.5 mL/kg/hr.

MeSH terms

  • Creatinine / blood
  • Ductus Arteriosus, Patent / drug therapy*
  • Humans
  • Indomethacin / adverse effects*
  • Infant, Newborn
  • Infant, Premature, Diseases / drug therapy
  • Oliguria / chemically induced*
  • Prognosis

Substances

  • Creatinine
  • Indomethacin